Trial reportUnited European gastroenterology journal2026
Histopathological Findings of Appendix Specimens in Quiescent Ulcerative Colitis: Correlations With Clinical Outcomes in the ACCURE Trial.
Trial report in United European gastroenterology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Histopathological Findings of Appendix Specimens in Quiescent Ulcerative Colitis: Correlations With Clinical Outcomes in the ACCURE Trial.United European gastroenterology journal · 2026Trial
- UEG Journal-In Times of Turmoil, Science Matters.United European gastroenterology journal · 2026Article
- The appendix and ulcerative colitis: from an unsolved connection to a therapeutic strategy.Translational gastroenterology and hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe ACCURE trial demonstrated that appendicectomy reduces relapse rates within 1 year in patients with ulcerative colitis (UC) in remission. We aimed to explore appendiceal histopathology in quiescent UC and assess its association with postoperative relapse.
methodsAppendix specimens from Dutch participants in the ACCURE trial were reassessed by a blinded gastrointestinal pathologist using the Robarts Histopathology Index (RHI; range 0-33). Active appendiceal inflammation was defined as RHI > 3. Clinical data, preoperative endoscopic findings including peri-appendiceal red patch (PARP), and outcomes were correlated with histopathological findings. Inter-observer agreement between local and central scoring was assessed, along with relapse-free survival in relation to RHI severity.
resultsOf 65 patients, 49 (75.4%) maintained remission and 16 (24.6%) relapsed within one year. Active inflammation was present in 55.4% (36/65). Inter-observer agreement was moderate (κ = 0.47, 95% CI 0.29-0.64, p < 0.001). Inflammation was more frequent in patients diagnosed at a younger age (median 28 vs. 34 years, p = 0.09), and greater in those with PARP (RHI 15.5 vs. 5.0, p = 0.005). Extensive epithelial neutrophil involvement (> 5% of crypts) was associated with higher relapse rates (44.4% vs. 18.0%, p = 0.05). Relapsing patients also had larger appendiceal diameters (median 9 vs. 7 mm, p = 0.03).
conclusionActive appendiceal inflammation is prevalent in quiescent UC and showed a trend toward association with relapse risk. Although the benefit of appendicectomy in this group cannot be confirmed on these data alone, the finding might be clinically relevant as relapse rates are significantly reduced in the appendicectomy group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.